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ABSTRACT 
Although well recognized for the regulation of peripheral metabolism, an 
emerging body of literature has begun to also establish a role for insulin in neural-
cardiovascular control.  In this regard, direct administration of insulin into the brain of 
experimental animals, or acute elevations in plasma insulin in healthy humans, results in 
robust increases in sympathetic nerve activity.  In addition to evoking increases in central 
sympathetic outflow, recent work in rats has reported a modulatory role for insulin in the 
regulation of arterial baroreflex control of sympathetic nerve activity.  The experiments 
within this dissertation were designed to further the understanding of insulin’s role in 
modulating central sympathetic outflow in humans.  The data presented demonstrate that 
an enhancement in insulin sensitivity increases insulin-mediated sympatho-excitation.  
Furthermore, we provide evidence for the first time that insulin increases the gain (i.e. 
sensitivity) of arterial baroreflex control of sympathetic nerve activity in healthy humans.  
Lastly, results are also presented in which we have begun to translate this area of research 
to a condition of chronic insulin resistance; type II diabetes mellitus.  Collectively, the 
findings further our understanding of insulin in neural-cardiovascular control by 
demonstrating a clear role for insulin in the regulation of central sympathetic outflow in 
humans. 
 
 
1 
 
Chapter 1.  Introduction 
 
The sympathetic nervous system, a subdivision of the autonomic nervous system, 
is involved in the unconscious control of almost every organ in the body.  Efferent 
sympathetic nerves, arising from the thoraco-lumbar section of the spinal cord innervate 
numerous tissues and exert effector action via the release of the neurotransmitter 
norepinephrine.  Although the sympathetic nervous system works in concert with the 
parasympathetic division of the autonomic nervous system, as well as local regulatory 
mechanisms, to determine the end organ response, the information presented within this 
dissertation will focus primarily on the sympathetic nervous system.  As stated by Walter 
B. Cannon in The Wisdom of the Body (1932) “It is the middle or thoraco-lumbar division 
[sympathetic] which acts promptly and directly to prevent serious changes of the internal 
environment. So important for homeostasis are the uses of this division that it deserves 
special and detailed consideration.”1 
In this regard, it is well established that the tonic rhythmic discharge of central 
sympathetic outflow is crucial for the control of vasomotor tone and arterial blood 
pressure2.  Indeed, stimulation of efferent sympathetic nerves leads to increases in arterial 
blood pressure, whereas denervation of theses nerves leads to falls in blood pressure2; 
illustrating the importance of the sympathetic nervous system in the maintenance of 
appropriate hemodynamic regulation.  However, in addition to the control of blood 
pressure, the sympathetic nervous system is also intimately involved in a wide array of 
physiological processes, ranging from renal to metabolic function3.   
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Central Sympathetic Overactivity 
The importance of the sympathetic nervous system is highlighted by a growing 
body of literature demonstrating that a number of disease states exhibit chronically 
elevated sympathetic nerve activity, such as hypertension4 and heart failure5.  
Importantly, an enhanced sympathetic outflow is not only restricted to diseases of the 
cardiovascular system and has been described in obesity6, metabolic syndrome7, renal 
disease8, obstructive sleep apnea9, pre-eclampsia10, depression11, ulcerative colitis12 and 
cirrhosis13.  The clinical significance of a chronically active sympathetic nervous system 
is further illustrated by findings demonstrating that sympathetic overactivity is associated 
with greater one-year cardiac mortality in heart failure patients14, is an independent 
predictor for the occurrence of cardiovascular events in end-stage renal disease patients15, 
16, and is associated with reduced functionality in elderly adults17.  In this regard, 
numerous detrimental physiological effects have been attributed to increased central 
sympathetic outflow. 
An important deleterious consequence of a chronically overactive sympathetic 
nervous system is an elevation in arterial blood pressure.  Indeed, it has been postulated 
that increases in sympathetic nerve activity play a significant role in both the initiation 
and development of hypertension18-21.  While a hypertensive state will contribute to 
structural and functional abnormalities of the vasculature (i.e. vascular remodeling)22, 23, 
elevated central sympathetic outflow, independent of a rise in arterial blood pressure, has 
been shown to elicit vascular smooth muscle cell hypertrophy and proliferation24, 25, 
impair endothelial cell function26, 27 and decrease arterial compliance28-30.  In addition to 
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unfavorable effects on the vasculature, exaggerated increases in sympathetic nerve 
activity have also been shown to induce detrimental effects on the cardiac (e.g. increased 
arrythmias)31, renal (e.g. glomerulosclerosis)32 and metabolic (e.g. dyslipidemia) 
systems33, 34.  The potential pathological consequences of elevated increases in central 
sympathetic outflow are highlighted in Table 1 and have been extensively described in a 
recent review from our laboratory3.  Although the mechanisms contributing to 
sympathetic overactivity in disease states remains an area on ongoing investigation, 
numerous findings have implicated alterations in the central control of sympathetic 
outflow. 
 
Central Control of Sympathetic Outflow 
The central regulation of sympathetic outflow is controlled by distinct nuclei 
within brainstem and hypothalamic regions which project directly to sympathetic 
preganglionic neurons located in the intermediolateral cell column of the spinal cord35, 36.  
Using retrograde transneuronal cell labeling, Strack et al37 identified that sympathetic 
preganglionic neurons receive inputs from five key areas of the brain; the paraventricular 
hypothalamic nucleus, A5 noradrenergic cell group, caudal raphe regions, rostral 
ventrolateral medulla and the ventromedial medulla.  Excitatory drive from these central 
sympathetic areas may be intrinsically generated or chemically mediated (e.g. 
glutamate)35, 36.  Nuclei involved in the control of sympathetic outflow may also be 
modulated by excitatory and inhibitory inputs from other regions within the central 
nervous system; such as the circumventricular organs which lack a blood brain barrier  
4 
 
Table 1.1  Potential pathological consequences of elevated central sympathetic nerve 
activity 
VSM, vascular smooth muscle; RAAS, Renin-angiotensin-aldosterone system 
 
    Incidence of arrhythmia
  
Vascular effects   Cardiac effects
     VSM cell hypertrophy and proliferation     Cardiac myocyte hypertrophy
     Medial thickening       Left ventricular hypertrophy
     Endothelial cell damage ↑   
     Endothelial dysfunction     Tachycardia
     Arterial stiffness  
     ↑  
  
Blood pressure variability Renal effects
     ↑    Peripheral vascular resistance     Renal vasoconstriction   
     Hypertension       Sodium and fluid retention
     Atherosclerosis        Glomerulosclerosis  
    Microalbumineria   
Metabolic effects       RAAS activation    
     Insulin resistance  
          Dyslipidemia  
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and are therefore responsive to blood-borne factors35, 38.  In addition, numerous peripheral 
afferent inputs, including but not limited to the arterial and cardiopulmonary 
baroreceptors, chemosensitive receptors, and visceral and gastrointestinal inputs, 
contribute to reflexive alterations in sympathetic outflow, via brainstem pathways35, 39.  
As such, complex neuroanatomical interactions exist in which descending excitatory 
input from central neuronal regions, afferent reflex modulation and/or reciprocal 
interactions among brain regions, ultimately determines efferent sympathetic outflow. 
 
Arterial Baroreflex Control of Sympathetic Nerve Activity 
 Although a number of afferent reflex pathways are involved in the modulation of 
the autonomic nervous system, due to the importance of sympathetic nerve activity in 
blood pressure homeostasis, the arterial baroreflex has received a considerable amount of 
attention.  Arterial baroreceptors are comprised of free nerve endings located within the 
carotid sinus and aortic arch.  Afferent neural signals from the carotid and aortic 
baroreceptors are relayed via cranial nerves IX (glossopharyngeal) and X (vagus), 
respectively40-42.  Arterial baroreceptor afferents terminate at the nucleus tractus solitarius 
(NTS) in the medulla oblongata35, 40.  The NTS exerts a tonic sympathoinhibitory 
influence on the rostral ventrolateral medulla (one of the central sympathoexcitatory 
regions), by relay projections to the caudal ventrolateral medulla (Figure 1)35, 36, 40.  
Through this central pathway, when arterial blood pressure is increased, the carotid and 
aortic baroreceptors are deformed, causing an increase in afferent neuronal firing and a 
reflex mediated decrease in sympathetic nerve activity.  Conversely, when arterial blood 
pressure is lowered, afferent neuronal firing is reduced, resulting in an increase in 
6 
 
sympathetic nerve activity40-42.  In both scenarios, the neural mediated changes in 
sympathetic outflow will function in the appropriate fashion to return arterial blood 
pressure to its original level.   
 The necessity of the arterial baroreflex for appropriate regulation of beat-to-beat 
blood pressure is illustrated in studies examining humans with baroreflex failure.  
Patients with denervation of the carotid baroreflex, due to complications of carotid tumor 
resection43, neck irradiation44, 45 or carotid endartectomy46, demonstrate excessive rises 
and falls in blood pressure to physiological stressors, such as orthostasis, cold stress or 
mental tasks.  Moreover, baroreflex denervation in humans and animal leads to large 
increases in blood pressure variability47; further highlighting the importance of the 
arterial baroreflex in the short term control of arterial blood pressure.  Interestingly, early 
and more recent findings have demonstrated that chronic carotid baroreceptor stimulation 
in hypertensive dogs48-50 and humans51-53 leads to sustained and clinically relevant 
decreases in arterial blood pressure and sympathetic nerve activity.  As such, these 
findings lend support for the arterial baroreflex in the long term control of sympathetic 
nerve activity and blood pressure; although, to date, this concept is not universally 
accepted54. 
 
Insulin and the Insulin Receptor within the Brain 
 Since the first description in 1889 that removal of the pancreas in dogs resulted in 
high levels of sugar in the urine55, and the subsequent discovery that a pancreatic extract, 
insulin, was capable of lowering blood glucose56, a plethora of research has been 
dedicated to understanding the metabolic actions of insulin.  Indeed, it is well established 
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that insulin has profound metabolic effects, including stimulation of glucose uptake, 
glycogen storage control, and inhibition of lypolysis57.  However, an emerging body of 
literature has indicated that, in addition to a role in metabolic control, insulin is a 
pleiotropic hormone with widespread mechanisms of action, including functions within 
the central nervous system. 
 Insulin is synthesized within the beta (β) cells of the Islets of Langerhans in the 
pancreas.  The β cells produce insulin from a proinsulin precursor, via the action of 
several proteolytic enzymes, ultimately resulting in a 51 amino acid polypeptide.  The 
primary stimulus for insulin release from the β-cells is an increase in plasma glucose.  In 
addition, amino and fatty acids, as well as acetylcholine stimulation of β2 adrenergic 
receptors can induce insulin release, although to a lesser extent57, 58.  Insulin exerts it 
actions via binding to the insulin receptor, a tyrosine kinase transmembrane receptor58, 59.  
The insulin receptor is composed of two ligand binding α subunits, linked by disulfide 
bonds to two membrane-spanning β subunits.  Binding of insulin to the α subunits 
stimulates intrinsic tyrosine kinase activity within the β subunits, resulting in 
phosphorylation of downstream proteins and initiation of numerous signaling cascades, 
including the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase 
(MAPK) pathways58, 59.  
Insulin receptors are widely dispersed throughout the body, including numerous, 
yet discrete sites within the central nervous system59-63.  In vitro work from rats has 
indicated that brain insulin receptor density is highest in the choroid plexus, olfactory 
bulb and hypothalamus, with moderate to low levels in other regions such as the cerebral 
cortex, brainstem and circumventricular organs61, 62.  Although insulin is not produced in 
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significant amounts within the central nervous system, increases in circulating insulin 
(via pancreatic release) gain access to the brain via transport mediated uptake across the 
blood brain barrier61, 63.  In this context, insulin has been shown to be involved in many 
divergent functions in the central nervous system, including effects on appetite 
regulation, peripheral metabolism, cognition, and neurotrophic effects60, 61.  Moreover, 
the finding that the ligand and the receptor are present in central neuro-cardiovascular 
control areas, including hypothalamic regions, circumventricular organs and the 
brainstem, has led to the concept that insulin may be involved in the control of 
sympathetic outflow64.   
 
Influence of Insulin on Central Sympathetic Outflow  
A role for insulin in central sympathetic control is drawn from studies in 
experimental animals, whereby intracerebroventricular administration of insulin elicits 
robust increases in peripheral sympathetic nerve activity65, 66.  Interestingly, insulin-
stimulated increases in central sympathetic outflow appear to be dose specific, as 
increases in lumbar and brown adipose tissue nerve activity were noted with low dose 
intracerebroventricular insulin infusion, whereas adrenal and renal sympathetic nerve 
activity were activated at higher dosages66.  In line with these findings, acute euglycemic 
hyperinsulinemia67-71 or ingestion of a mixed meal72-74 or glucose load75-79 (to increase 
plasma insulin) have been shown to stimulate increases in muscle sympathetic nerve 
activity in humans.  Importantly, elevations in plasma insulin could increase sympathetic 
nerve activity via indirect mechanisms; nonetheless, several lines of evidence are 
consistent with the hypothesis that hyperinsulinemia induced increases in sympathetic 
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outflow are primarily due to a central effect.  First, insulin has vasodilatory actions and 
therefore a drop in arterial blood pressure during peripheral hyperinsulinemia could 
mediate a baroreflex-mediated increase in sympathetic nerve activity.  However, in 
humans, the increase in muscle sympathetic nerve activity is also present during low dose 
euglycemic hyperinsulinemia, in which peripheral vasodilation does not occur69; arguing 
against a baroreflex-mediated increase in sympathetic outflow.  In addition, Vollenweider 
et al71 infused insulin and fructose into normotensive humans to examine if insulin 
elevates sympathetic nerve activity through indirect actions of the hormone on 
carbohydrate metabolism and oxidation.  While insulin and fructose produced 
comparable increases in carbohydrate metabolism, only infusion of insulin was 
associated with elevated muscle sympathetic nerve activity.  Collectively, these studies, 
utilizing a variety of maneuvers to alter brain and plasma insulin concentrations, 
demonstrate a central sympatho-excitatory effect of insulin. 
 Although the precise central region(s) involved in mediating insulin-stimulated 
increases in sympathetic outflow remain unclear, several areas are worthy of 
consideration.  The anteroventral third ventricle (AV3V) region, an area containing 
several of the circumventricular organs (organum vasculosum lamina terminalis and 
subfornical organ) is well recognized as a neuronal region involved in the detection of 
blood-borne signals.  Interestingly, lesioning of the AV3V region prevents the increase in 
lumbar sympathetic nerve activity in response to euglycemic hyperinsulinemia80.  
Furthermore, studies demonstrating robust increases in lumbar sympathetic nerve activity 
in response to lateral ventricular infusion of insulin in rats81, suggests that a hypothalamic 
region, such as the paraventricular nucleus, may be involved.  In line with this, Rahmouni 
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et al66 have shown that global hypothalamic inhibition of PI3K blocked insulin-mediated 
increases in lumbar sympathetic nerve activity, whereas MAPK inhibition specifically 
blocked insulin-induced increases in sympathetic nerve activity to brown adipose tissue.  
Moreover, very recent findings suggest that an excitatory glutamatergic pathway to the 
brainstem may be involved in insulin stimulated sympatho-excitation82.  Indeed, 
microinjection of kynurenic acid, a glutamate receptor antagonist, into the rostral ventral 
lateral medulla significantly reduced lumbar sympathetic nerve activity during 
hyperinsulinemic euglycemic clamps in rats.  Of note, insulin microinjection directly into 
the rostral ventral lateral medulla did not alter lumber sympathetic nerve activity82.  
Taken together these findings lend insight into the potential neural pathways and 
signaling mechanisms involved in insulin mediated increases in central sympathetic 
outflow (Figure 1); however, future studies are clearly warranted to further delineate the 
precise neuronal pathways and mechanisms of insulin action in neural-cardiovascular 
control. 
 
Insulin and Arterial Baroreflex Control of Sympathetic Nerve Activity 
In addition to a sympatho-excitatory role of insulin, emerging evidence from 
studies in experimental animals has begun to illustrate a role for insulin in the central 
modulation of the arterial baroreflex.  Recently, Pricher et al81 demonstrated that 
increases in insulin within the brain, via lateral ventricular infusion, enhanced the gain 
(i.e. sensitivity) of arterial baroreflex control of lumbar sympathetic nerve activity in rats.  
Other studies have indicated that neurons in central baroreflex regulatory regions (i.e. 
nucleus tractus solitarius) are responsive to insulin83.  Collectively, these studies indicate  
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Figure 1.1 Schematic summarizing neural pathways that may play a role in insulin 
mediated control of sympathetic outflow.  Cardiovascular regulatory regions in the 
forebrain, hypothalamus and brainstem may all contribute. Circumventricular organs 
within the anteroventral third ventricle region (outlined with dashed lines) may sense 
increases in circulating insulin and project directly or indirectly to hypothalamic regions.  
In addition, the paraventricular hypothalamic nucleus (PVN) demonstrates a high binding 
density of insulin (dark grey) and may also directly influence sympathetic outflow via 
projections to the intermediolateral cell column of the spinal cord (IML) or indirectly 
through projections to brainstem regions.  Insulin could also modulate sympathetic 
outflow within brainstem regions such as the nucleus tractus solitarius (NTS), caudal 
ventral lateral medulla (CVLM) and rostral ventral lateral medulla (RVLM).  Arterial 
baroreflex afferents terminate within the NTS and as such insulin may modulate arterial 
baroreflex control of sympathetic nerve activity by directly acting within brainstem 
regions or via impinging neural inputs from other brain regions.   
OVLT, organum vasculosum lamina terminalis; SFO, subfornical organ. Sagital brain 
section adapted from Zimmerman & Davisson, Prog Biophys Mol Biol, 2004. 
NTS
RVLM
CVLM
PVN
SFO
OVLT
IML
Sympathetic 
Nerve Activity
Arterial Baroreflex & 
Other Afferent Inputs
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that insulin may directly influence arterial baroreflex function within central neural 
cardiovascular control pathways.  However, studies in this area are limited and, to date, 
no work has been performed in humans evaluating the potential influence of insulin on 
arterial baroreflex control of sympathetic nerve activity.   
 
Insulin Mediated Sympatho-excitation and Arterial Baroreflex Control in Insulin 
Resistant Conditions 
 Numerous physiological and pathophysiological conditions are characterized by a 
decreased sensitivity to the actions of insulin (i.e. insulin resistance), including type II 
diabetes mellitus, hypertension, obesity, metabolic syndrome and pregnancy.  
Interestingly, recent studies have suggested that insulin-mediated sympatho-excitation 
may be impaired in insulin resistant conditions76, 78, 79, 84.  Indeed, obese individuals84, 
insulin resistant elderly subjects76 and metabolic syndrome patients78, 79 all demonstrate 
attenuated increases in muscle sympathetic nerve activity in response to 
hyperinsulinemia.  As such, in addition to peripheral insulin resistance, insulin resistant 
conditions may also exhibit a central resistance to the actions of insulin.  In line with this 
concept, recent studies indicate that insulin resistant states are accompanied by reduced 
cerebrospinal fluid insulin concentrations63, 85-87.  This reduction in insulin likely 
emanates from an attenuated transport of insulin into the central nervous system, as 
pharmacologically and diet induced insulin resistance in animal models has been shown 
to reduce central nervous system insulin uptake85, 86, whereas brain endothelial cells of 
obese rats demonstrate impaired insulin binding88.   
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In addition to impaired insulin-mediated sympatho-excitation, insulin resistant 
conditions are commonly characterized by impairments in arterial baroreflex control of 
sympathetic nerve activity7, 89-92.  Although not causative, the concomitant occurrence of 
insulin resistance with reductions in arterial baroreflex function clearly suggests a link 
between the two.  Given that cerebral spinal fluid levels of insulin are reduced in insulin 
resistant conditions63, 85-87 and that insulin in the brain enhances arterial baroreflex control 
of sympathetic outflow81; Brooks and colleagues have advanced the hypothesis that a 
certain level of insulin within the brain is essential for normal arterial baroreflex 
function81, 93, 94.  However, while arterial baroreflex-sympathetic control has been shown 
to be reduced in hypertension89, 90, 92, 95, obesity91 and metabolic syndrome7, information 
on other insulin resistant conditions, such as type II diabetes mellitus, is currently 
lacking. 
 
Summary 
 Although once thought to only be crucial for the regulation of peripheral 
metabolism, an emerging body of literature has established a role for insulin in neural-
cardiovascular control.  In healthy humans, elevations in plasma insulin during 
physiological72-79 (i.e. meal intake) or experimental67-71 perturbations results in robust 
increases in muscle sympathetic nerve activity; a response that has been primarily 
attributed to a central effect of insulin.  Furthermore, direct administration of insulin into 
the brain of experimental animals also evokes increases in peripheral nerve activity65, 66, 
81, although the precise neural regions and/or mechanisms remain incompletely defined.  
In addition to evoking increases in sympathetic outflow, recent work in rats has reported 
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a role for insulin in the modulation of the arterial baroreflex81.  The following projects 
were designed to extend this growing area of research and to examine a role for insulin in 
the control of central sympathetic outflow in humans.  Specifically, the influence of 
insulin sensitivity on insulin-mediated sympatho-excitation, a role for insulin in the 
modulation of arterial baroreflex control of muscle sympathetic nerve activity, and 
translation of these findings to an insulin resistant disease state, type II diabetes mellitus, 
will be presented. 
 
Specific Aims 
Aim 1:  Previous studies have reported that insulin resistant conditions are associated 
with impaired insulin-mediated sympatho-excitation76, 78, 79, 84.  Importantly, in these 
previous investigations, the populations studied were all characterized by resting 
sympathetic overactivity.  Therefore, it is possible that the sympathetic responses to 
insulin may have been influenced by higher basal sympathetic activity (i.e. a ceiling 
effect).  Thus, the focus of Aim 1 was to determine if differences in insulin-stimulated 
sympatho-excitation occur without confounding factors such as elevated resting 
sympathetic activity, body mass, or age.  To examine this, we studied two healthy subject 
groups, with distinct differences in insulin sensitivity, to investigate how insulin 
sensitivity influences insulin-mediated changes in central sympathetic outflow. 
 
Aim 2:  Recent findings in rats have demonstrated that insulin in the brain enhances 
arterial baroreflex control of sympathetic nerve activity81; however, the extent to which 
these findings can be translated to humans remains unknown.  Therefore, Aim 2 was 
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designed to examine the influence of insulin on arterial baroreflex control of muscle 
sympathetic nerve activity in healthy humans. 
 
Aim 3:  Although numerous insulin resistant conditions are characterized by a reduction 
in arterial baroreflex control of sympathetic nerve activity, surprisingly an examination of 
the sympathetic arterial baroreflex has not been performed in type II diabetes mellitus.  
Thus, Aim 3 was designed to begin to investigate arterial baroreflex control of muscle 
sympathetic nerve activity in patients with type II diabetes. 
16 
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ABSTRACT 
Nutrient intake is accompanied by increases in central sympathetic outflow; a response 
that has been mainly attributed to insulin. Insulin-mediated sympatho-excitation appears to be 
blunted in insulin resistant conditions suggesting that aside from peripheral insulin insensitivity, 
such conditions may also impair the central action of insulin in mediating sympathetic activation. 
What remains unclear is whether an insulin sensitive state, such as that induced by chronic 
endurance training, alters the central sympathetic effects of insulin during postprandial 
conditions. To examine this question plasma insulin and glucose, muscle sympathetic nerve 
activity (MSNA), heart rate, and arterial blood pressure were measured in 11 high fit (HF; VO2 
65.9±1.4 ml•kg-1•min-1) and 9 average fit (AF; VO2 43.6±1.3 ml•kg-1•min-1) male subjects before 
and for 120 minutes after ingestion of a mixed meal drink. As expected, the insulin response to 
meal ingestion was lower in HF than AF participants (insulin area under the curve0-120: 2314±171 
vs. 4028±460 uIU•ml-1•120-1, HF vs. AF, P<0.05), with similar plasma glucose responses 
between groups. Importantly, following consumption of the meal, the HF subjects demonstrated 
a greater rise in MSNA, when compared to the AF subjects (e.g. 120 minutes: Δ21±1 vs. 8±3 
bursts•100 heart beats-1, HF vs. AF, P<0.05).  Furthermore, when expressed relative to plasma 
insulin, HF subjects exhibited a greater change in MSNA for any given change in insulin. 
Arterial blood pressure responses following meal intake were similar between groups. 
Collectively, these data suggest that, in addition to improved peripheral insulin sensitivity, 
endurance training may enhance the central sympathetic effect of insulin to increase MSNA 
following consumption of a mixed meal. 
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INTRODUCTION 
 It is well recognized that acute nutrient intake is accompanied by robust increases in 
central sympathetic outflow1-3. Presumably, the physiological relevance of an increase in 
sympathetic neural activity is to facilitate blood flow redistribution and for the overall 
maintenance of arterial blood pressure1-4.  In addition, increases in sympathetic outflow will 
stimulate facultative thermogenesis (e.g. diet-induced thermogenesis)5-7 and may enhance 
glucose uptake in skeletal muscle and adipose tissue8-12. While a variety of factors may be 
implicated, numerous findings have indicated that the large rise in plasma insulin concentrations 
following meal intake is an important mediator of the postprandial increase in central 
sympathetic outflow3, 13. 
 A central sympatho-excitatory action of insulin is drawn from studies in experimental 
animals, whereby intracerebroventricular administration of insulin elicits robust increases in 
peripheral sympathetic nerve activity14, 15.  In line with these findings, a mixed meal13, 16, glucose 
load17-21 and acute euglycemic hyperinsulinemia4, 22-25 have been shown to stimulate increases in 
muscle sympathetic nerve activity (MSNA) in humans.  Importantly, the increase in MSNA is 
also present during low dose euglycemic hyperinsulinemia, in which peripheral vasodilation does 
not occur 24; consistent with the hypothesis that hyperinsulinemia induced increases in 
sympathetic outflow are primarily due to a central effect (i.e. non baroreflex-mediated).  Overall, 
these studies, utilizing a variety of maneuvers to alter plasma insulin concentrations, demonstrate 
that elevations in insulin stimulate increases in central sympathetic outflow. 
 Recent studies have suggested that insulin-mediated sympatho-excitation may be 
impaired in insulin resistant conditions.  Indeed, Vollenweider et al26 demonstrated that obese 
individuals exhibited attenuated MSNA responses to euglycemic hyperinsulinemia, despite 
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higher insulin concentrations, when compared to lean subjects.  Findings in insulin resistant 
elderly subjects18 and insulin resistant metabolic syndrome patients20, 21 have similarly reported a 
blunted sympathetic response to increases in plasma insulin following a glucose load.  As such, 
in addition to peripheral insulin resistance, insulin resistant conditions may also exhibit a central 
resistance to the actions of insulin.  In line with this concept, recent studies indicate that insulin 
resistant states are accompanied by reduced cerebrospinal fluid insulin concentrations, likely 
emanating from an attenuated transport of insulin into the central nervous system27-30.  However, 
while an insulin resistant condition appears to impair insulin-mediated sympatho-excitation, the 
influence of enhanced insulin sensitivity on insulin-induced increases in central sympathetic 
outflow remains unclear.  
 To begin to examine this question we recruited healthy endurance trained (high fit, HF) 
and normally active (average fit, AF) subjects.  It is well characterized that chronic endurance 
training results in enhanced peripheral insulin sensitivity31-35.  Therefore, our rationale was that 
inclusion of two healthy subject groups, with distinct differences in insulin sensitivity, would 
allow us to investigate how enhanced insulin sensitivity influences insulin-mediated changes in 
central sympathetic outflow. Direct measurements of central sympathetic outflow to skeletal 
muscle (i.e., MSNA) were recorded and a mixed meal was used as a physiological method to 
evoke robust and sustained increases in MSNA, which have been primarily attributed to insulin3, 
13.  We hypothesized that HF subjects would have a greater MSNA response, for a given plasma 
insulin concentration, following consumption of a mixed meal (i.e., greater central insulin 
sensitivity). 
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METHODS 
Twenty healthy men volunteered for participation in the study. Subjects were 
asymptomatic for cardiovascular, respiratory or metabolic disease and were not taking any 
medications.  The subject population consisted of eleven HF and nine AF men.  HF subjects 
were all competitive endurance athletes (i.e. marathon runners and triathletes) and had been 
competing in endurance events for 9 ± 1 years with weekly exercise regimens including 12 ± 2 
hours per week of training.  In contrast, AF subjects were only recreationally active, engaging in 
aerobic activities for less than 30 minutes, ≤3 days per week reporting physical activities 
amounting to 45 ± 23 minutes per week.  When recruiting HF subjects a peak oxygen uptake 
(VO2peak) of ≥ 60ml/kg/min was used as the cutoff for inclusion.  For the AF subjects we initially 
attempted to enroll subjects with a VO2peak ≤ 45 ml/kg/min, however, this proved difficult for 
young healthy lean subjects and therefore, we had two subjects with a VO2peak of 47 ml/kg/min in 
this group. A greater number of HF compared to AF subjects were recruited due to difficulty 
with MSNA measurements in this group (see MSNA section below).  All experimental 
procedures and protocols were approved by the University of Missouri Health Sciences 
Institutional Review Board. After receiving a detailed verbal and written explanation of the 
intended experimental protocol and measurements, each subject provided written informed 
consent prior to participation. 
 
Experimental Measurements 
General measurements:  Heart rate was continuously monitored using a lead II 
electrocardiogram (Quinton Q710, Bothell, WA, USA).  An automated sphygmomanometer 
(Welch Allyn, Skaneatles Falls, NY, USA) was used to measure arterial blood pressure by 
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auscultation of the brachial artery of the right arm.  Respiratory movements were monitored 
using a strain-gauge pneumograph placed in a stable position around the abdomen (Pneumotrace, 
UFI, Morro Bay, CA, USA).   
Plasma Insulin and Glucose:  Venous blood samples were drawn from an antecubital 
intravenous catheter for the measurements of plasma glucose and insulin.  Glucose was analyzed 
using the glucose oxidase method (Thermo, Waltham, MA, USA) and insulin was determined by 
chemiluminescent enzyme immunoassay (Immulite 1000 Analyzer, Diagnostic Products Corp., 
Los Angeles, CA, USA).  The areas under the glucose and insulin curves (AUC0-120) were 
calculated from values measured at baseline, using the trapezoidal method36.   
Muscle Sympathetic Nerve Activity (MSNA):  Multiunit recordings of postganglionic 
MSNA were obtained as described previously37-41.  Briefly, a unipolar tungsten microelectrode 
was inserted percutaneously through the intact, unanaesthetized skin and positioned into muscle 
nerve fascicles of the peroneal nerve near the fibular head of the left leg. Postganglionic 
sympathetic action potentials were amplified, filtered (bandwidth 700 – 2000 Hz), rectified, and 
integrated (time constant, 0.1 s) to obtain a mean voltage neurogram.  MSNA recordings were 
identified by their characteristic pulse-synchronous burst pattern and increased neural activity in 
response to an end-expiratory apnea or Valsalva maneuver, without any response to arousal 
stimuli or stroking of the skin37, 38, 41.  MSNA was not obtained in 4 HF subjects because an 
acceptable recording was not found in 2 subjects and recordings could not be maintained for the 
duration of the protocol in 2 others.   
MSNA was first identified by visual inspection, independently by 2 investigators, and 
was then analyzed using custom designed software (MatLab, The Math Works, Natick, MA, 
USA)42.  This program first detects peaks in the integrated neurogram based on a latency window 
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centered on each R wave from the electrocardiogram.  After the peaks are chosen, the the nearest 
minimum value on either side of the peak is detected, which is then denoted as the start and end 
of a sympathetic burst.  An algorithm is applied to validate each burst, which takes into account 
the slope of the rise and fall of the burst, as well as the magnitude.  The amplitude of the largest 
burst at baseline was assigned a value of 1000 (arbitrary units; AU) and all other bursts within a 
trial were normalized with respect to this value.  Sympathetic activity was quantified using 
standard measures, including burst frequency (bursts/min), burst incidence (bursts/100 heart 
beats), burst strength (burst area), and total activity (product of burst frequency and mean burst 
area).  However, because the absolute area of a burst is dependent on the location of the 
microelectrode in relation to the nerve fibers that are being recorded, which cannot be 
determined, direct comparisons of burst strength, and total activity between groups is typically 
not performed. Although various normalization procedures have previously been applied, these 
cannot completely account for the limitation associated with potential differences in electrode 
placement between individuals and, ultimately, subject groups43-45. For example, calculating a 
percentage change in total activity from baseline will be affected by differences in resting total 
activity (i.e. microelectrode placement) and not necessarily reflect a difference in sympathetic 
responsiveness between two groups. In this manuscript, multiple MSNA data are included in an 
effort to be complete; however we focused our results on measures of sympathetic bursts, which 
have been shown to be reproducible over time in the same subject and comparable between 
groups (50). Furthermore, because of group differences in heart rate and the inherent cardiac 
synchronicity of MSNA37, 38, 41, we used MSNA burst incidence for our main comparison 
between groups. In addition, the area under the MSNA burst incidence curve (AUC0-120) was 
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calculated for each subject using the trapezoidal method36 and related to the insulin AUC0-120 as 
described previously21. 
Femoral artery blood flow:  Femoral blood flow (FBF) was obtained in the right leg 
using a duplex Doppler ultrasound unit (Logiq 7, GE Medical Systems, Milwaukee, WI) 
equipped with a linear array transducer operating at a frequency of 10 MHz.  The common 
femoral artery was imaged 2-3 cm proximal to the bifurcation of the superficial and deep 
branches.  Femoral blood velocity was obtained using the same probe in pulsed-wave mode, 
operating at a linear frequency of 5 Hz and at an insonation angle of 60°.  Arterial diameter and 
mean blood velocity (Vmean) were calculated using commercially available software (Logiq 7, GE 
Medical Systems, Milwaukee, WI, USA).  Using femoral artery diameter and Vmean, FBF was 
calculated as: FBF = Vmean•π•(femoral artery diameter/2)2•60.  FBF was normalized to right leg 
lean mass for group comparisons.  Femoral vascular conductance (FVC) was calculated using the 
formula: FVC = FBF / mean arterial blood pressure. 
 
Experimental Protocols 
Visit 1:  Subjects were familiarized with the experimental protocols and procedures, after 
which a whole body dual-energy X-ray absorptometry scan (Hologic Delphi A, Waltham, MA) 
was performed to obtain right leg lean muscle mass, used to normalize blood flow measures 
between groups.  In addition, in order to ascertain VO2peak, all subjects underwent a graded 
treadmill exercise test (Bruce Protocol) to exhaustion and maximal effort was determined 
according to established criteria46. 
Visit 2:  Subjects reported to the laboratory on a separate occasion at least 5 days after 
completion of the first visit and were instructed to abstain from caffeinated beverages and food 
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for 12 hours, alcohol for 24 hours, and physical activity for 48 hours prior to the experimental 
session.  The latter instruction was used to minimize the influence of acute physical activity 
effects on insulin sensitivity47, 48. Subjects were placed in the supine position on a medical 
examination table and were instrumented for measures of heart rate, arterial blood pressure, 
MSNA, FBF and an intravenous catheter was placed in an antecubital vein.  Baseline variables 
were collected for a period of 20 minutes and a pre-meal blood draw was taken, after which 
subjects ingested a mixed meal drink (Ensure Plus, Abbott Laboratories, Columbus, Ohio, USA; 
57% CHO, 28% Fat, 15% Protein) corresponding to 20% of their estimated energy expenditure 
calculated from body weight49.  The calories consumed were similar between groups (521 ± 9 vs. 
533 ± 14 KCals, HF vs. AF, P>0.05).  All variables were measured for a 5 minute period, every 
15 minutes, for 120 minutes following consumption of the mixed meal.   Venous blood samples 
were also drawn every 15 minutes and the resulting plasma was stored at -80° C for later analysis 
of plasma glucose and insulin concentrations. 
 
Data Analysis 
 Heart rate and MSNA were sampled at 1000Hz and stored for off-line analysis (Chart 
v5.2 and Powerlab, ADInstruments, Bella Vista, NSW, Australia).  Baseline heart rate, arterial 
blood pressure, MSNA and FBF were calculated as mean values over a 6 minute period.  
Following consumption of the mixed meal, 3 minute averages were calculated from the 5 min 
data segments collected every 15 minutes.  The ratio of a change in MSNA burst incidence to a 
change in insulin was evaluated at each time point for individual subjects as an index of the 
sympathetic response for a given concentration of plasma insulin. 
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Statistical analysis 
Statistical comparisons of physiological variables were conducted using a 2-way analyses 
of variance (fitness•time) with repeated measures and a Tukey test was employed post hoc when 
significant main effects were found.  Statistical significance was set at P < 0.05 and analyses 
were conducted using SigmaStat (Jandel Scientific Software, SPSS Inc., Chicago, IL, USA) for 
Windows.  Statistical comparisons were performed using all time points following meal intake.  
However, for presentation purposes, only 30 minute time points are reported in some cases.  
Results are presented as means ± standard error (SE).  
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RESULTS 
 Subject characteristics:  Age, height, weight and body mass index did not differ between 
groups (Table 2.1).  Similarly, fasting plasma glucose and insulin were not different between 
groups (Table 2.1 and Figure 2.1).  As anticipated, the HF subjects had a higher VO2peak than the 
AF subjects, with a mean group difference greater than 20 ml/kg/min (Range: HF 60-73 
ml/kg/min, AF 36-47 ml/kg/min).  HF subjects exhibited a significantly lower heart rate at 
baseline, whereas resting systolic (SBP), diastolic (DBP) and mean arterial blood pressure 
(MBP) were similar between groups (Table 2.2). 
 Metabolic responses to a mixed meal:  Mixed meal intake induced a significant rise in 
plasma glucose, with similar responses between groups at each time point (Figure 2.1A) and 
when quantified as glucose AUC (Figure 2.1C).  In contrast, HF subjects demonstrated much 
less of an increase in plasma insulin, compared to the AF subjects (Figure 2.1B).  This enhanced 
insulin sensitivity in the HF subjects was illustrated by an approximately 45% lower insulin 
AUC0-120 (Figure 2.1D). 
 MSNA responses to a mixed meal:  At rest, MSNA burst incidence and burst frequency 
was comparable between groups (Figure 2.2, Figure 2.3, and Table 2.3).  Following ingestion of 
the mixed meal, the HF subjects demonstrated a greater rise in MSNA burst incidence, as well as 
burst frequency, compared to AF subjects.  Results obtained for MSNA total activity and burst 
strength are also provided in Table 2.3. 
MSNA : insulin relationships:  Figure 2.4 illustrates the ratios of a change in MSNA burst 
incidence to a change in plasma insulin, indicating that for a given change in insulin HF subjects 
had a greater change in MSNA burst incidence.  Similar results were found when relating the 
MSNA burst incidence AUC0-120 to the insulin AUC0-120 (Figure 2.4B). 
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FBF responses to a mixed meal:  Resting FBF was not different between groups.  In 
response to the mixed meal, FBF was increased above baseline values, with similar increases in 
the HF and AF subjects. Likewise, resting FVC was the same between groups and increased 
similarly in response to mixed meal ingestion (all Table 2.2).    
Cardiovascular responses to a mixed meal: Overall there were no differences in the 
arterial blood pressure responses to mixed meal intake between groups.  Following the mixed 
meal, SBP, DBP and MAP were slightly, but significantly increased in both groups.  Heart rate 
responses to the mixed meal were not different between groups and therefore heart rate was 
lower throughout the entire protocol in the HF compared to the AF subjects owing primarily to 
baseline differences (all Table 2.2). 
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DISCUSSION 
The major finding of the current study was that HF subjects demonstrated a greater 
increase in MSNA burst incidence compared to AF subjects following consumption of a mixed 
meal.  Importantly this greater sympathetic activation occurred despite lower plasma insulin 
concentrations, with comparable plasma glucose between groups.  Furthermore, when MSNA 
responses were expressed relative to plasma insulin, HF subjects exhibited a greater change in 
MSNA for any given change in insulin.  Collectively, these data suggest that, in addition to 
improved peripheral insulin sensitivity, endurance training may also enhance the central actions 
of insulin to increase MSNA following consumption of a mixed meal.  
Nutrient intake is accompanied by increases in central sympathetic outflow; a response 
that has been mainly attributed to insulin3, 13. In the current study we used chronic endurance 
training as a model to establish two distinct subject groups.  An enhancement in the peripheral 
sensitivity to the actions of insulin (i.e. glucose disposal) is well characterized with chronic 
endurance training31-35 and therefore, we rationalized that endurance trained individuals would 
exhibit a lower insulin response with similar glucose concentrations following the mixed meal.  
Furthermore, if enhanced central insulin sensitivity was present, we reasoned that the HF 
subjects would exhibit a similar or greater increase in MSNA despite the lower plasma insulin.  
Indeed, following consumption of the mixed meal, the HF subjects demonstrated a significantly 
larger increase in MSNA when compared to the AF subjects.   
From our direct sympathetic recordings, an increase in central sympathetic outflow to 
skeletal muscle can be characterized by either an increase in efferent sympathetic impulses (i.e. 
burst incidence) or an increase in the strength of the sympathetic bursts (i.e. burst area) or a 
combination of the two50.  Interestingly, the rise in MSNA following nutrient intake was evident 
42 
 
when examining both burst occurrence (i.e. burst incidence), as well as burst strength in both 
groups.  These data suggest that the increase in central sympathetic outflow to skeletal muscle 
following a mixed meal is due to an enhanced sympathetic firing rate as well as enhanced 
neuronal recruitment50.  The larger increase in MSNA burst incidence in the HF compared to AF 
subjects clearly demonstrates a greater postprandial central sympatho-excitation.  In addition, the 
greater increases in burst strength in the HF group suggests that this fitness effect on MSNA may 
include greater neuronal recruitment51; however, group comparisons of burst strength need to be 
interpreted cautiously because the area of a burst is dependent on the location of the recording 
microelectrode, which cannot be determined38, 52.  Therefore, we focused our results on measures 
of sympathetic bursts, which have been shown to be reproducible over time in the same subject 
and comparable between groups52.  Furthermore, the use of MSNA burst incidence is warranted 
because of group differences in heart rate and the inherent cardiac synchronicity of MSNA37, 38, 
41. 
Following food intake, coordinated cardiovascular, metabolic and neural responses occur 
in order to distribute, absorb and store nutrients.  Postprandial activation of the sympathetic 
nervous system is crucial for blood flow redistribution and overall maintenance of arterial blood 
pressure1-3, 7.  Although a number of factors have been suggested3, several lines of evidence 
indicate that the elevation in plasma insulin following a meal plays a prominent role in 
stimulating the increases in central sympathetic outflow3, 13.  First, a strong positive correlation 
has been reported between plasma insulin and the increases in MSNA after a glucose meal in 
healthy subjects17, 53. Second, a mixed meal and glucose load have been shown to elicit the 
greatest changes in MSNA when compared to fat or protein intake alone, in which insulin 
secretion is minimal13. In addition, euglycemic hyperinsulinemia within the postprandial range 
43 
 
increases MSNA in healthy humans to a similar extent as that following a mixed meal24.  Third, 
recent animal studies have provided clear evidence indicating a direct action of insulin to 
increase central sympathetic outflow14, 15. Lastly, alterations in the sympathetic response to a 
mixed meal and glucose load have been identified in insulin resistant conditions18, 20, 21, 26. 
Overall, although insulin independent mechanisms cannot be completely discounted, these data 
indicate that a mixed meal represents a physiological method to investigate insulin-mediated 
stimulation of central sympathetic outflow. 
In the current study, when the MSNA burst incidence responses to the mixed meal were 
expressed relative to insulin, a greater change in sympathetic outflow for a given change in 
plasma insulin concentrations was noted in the HF group.  This held true whether the values 
were expressed at each time point or as a ratio of the MSNA AUC0-120 to the insulin AUC0-120. 
These data suggest that an enhancement in insulin sensitivity, even in otherwise healthy 
individuals, improves insulin stimulated sympatho-excitation to skeletal muscle (i.e. enhanced 
central insulin sensitivity).  Of note, MSNA burst frequency data also suggests that HF subjects 
exhibit greater central insulin sensitivity.  Although the physiological consequence of a greater 
increase in central sympathetic outflow in the HF subjects is beyond the scope of the current 
project, it may be that an augmentation in sympathetic outflow following mixed meal intake 
allows for greater control over redistribution of blood flow and absorption of nutrients; thus 
contributing to the enhanced peripheral insulin sensitivity. 
Recent investigations have suggested that the central stimulatory actions of insulin may 
be blunted in insulin resistant conditions18, 20, 21, 26.  Indeed, the sympatho-excitation following a 
mixed meal, glucose load or euglycemic hyperinsulinemic clamp is blunted in elderly insulin 
resistant individuals18, insulin resistant metabolic syndrome patients20, 21 and obese subjects26, 
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respectively.  In addition, Straznicky et al21 recently demonstrated that diet and exercise induced 
weight loss in insulin resistant metabolic syndrome subjects improved the blunted sympathetic 
responsiveness to a glucose load, as measured by whole body norepinephrine kinetics.  
Moreover, a positive correlation between maximal oxygen uptake and the insulin-induced 
increases in whole body norepinephrine spillover has been noted in metabolic syndrome 
patients20.  Taken together these findings suggest that an insulin resistant state may blunt insulin-
mediated sympathetic neural responses and that potential improvements in insulin sensitivity 
may restore insulin’s ability to increase sympathetic outflow.  The current findings are in 
agreement and extend this work by directly assessing MSNA in two groups of young, lean 
healthy individuals, who display distinct differences in insulin sensitivity (i.e., different 
postprandial insulin responses to a meal).  Importantly, in these previous investigations, the 
populations studied were all characterized by resting sympathetic overactivity.  Therefore, it is 
possible that the sympathetic responses to insulin may be influenced by higher basal sympathetic 
activity (i.e. a ceiling effect)54.  The current findings allowed us to determine if differences in 
insulin stimulated sympatho-excitation occur without confounding factors such as elevated 
resting sympathetic activity, body mass index, or age. 
While the exact mechanism(s) contributing to alterations in insulin stimulated changes in 
central sympathetic outflow to skeletal muscle remain unknown, several possibilities are worthy 
of consideration.  First, it is possible that alterations in insulin transport across the blood brain 
barrier occur with changes in insulin sensitivity.  In support of this concept, a reduced 
cerebrospinal fluid to plasma insulin ratio has been reported in obese individuals, with the ratio 
being highly negatively related to the degree of insulin resistance29.  Moreover, 
pharmacologically induced insulin resistance in animal models has been shown to reduce central 
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nervous system insulin uptake27, 28, whereas brain endothelial cells of obese rats demonstrate 
impaired insulin binding30.  Thus, our findings demonstrating a more robust increase in MSNA, 
in the HF compared to the AF subjects, may be due to differences in insulin delivery and/or rate 
of transport into the brain.  In addition, it is possible that central insulin-mediated signaling 
cascade pathways may be altered with changes in central insulin sensitivity.  Findings from 
rodent models suggest that insulin stimulated increases in sympathetic outflow primarily occur 
within hypothalamic regions through both the phosphoinositide 3-kinase and mitogen-activated 
protein kinase pathways14, 15, 55.  Given that both of these pathways have been shown to be 
modified in the periphery in insulin resistant states48 and in response to endurance training56, it is 
plausible that alterations in either of these signaling pathways within the central nervous system 
occurs with changes in insulin sensitivity.  
A role for insulin in mediating peripheral vasodilation has been well documented57-59.  
Although not the main focus of our study, considering the known increases in peripheral insulin 
sensitivity with endurance training31-35, one may have anticipated a greater insulin-mediated 
increase in blood flow in the HF, compared to the AF subjects, following the mixed meal.  
However, we did not observe any group differences in absolute FBF or FVC responses following 
ingestion of the mixed meal. In line with our findings, the peripheral blood flow responses 
following a glucose load in insulin resistant and insulin sensitive metabolic syndrome subjects 
have also been shown to not differ between groups with differences in insulin sensitivity20, 21.  It 
may be that the majority of insulin stimulated vasodilation following meal intake occurs within 
the microvasculature.  As discussed by Renkin and colleagues60, 61, enhancing capillary surface 
area will greatly increase nutrient delivery in direct proportion to the surface area available for 
nutrient exchange (e.g. microvascular recruitment), whereas increasing total limb blood flow (i.e. 
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FBF) would minimally enhance nutrient exchange.  Therefore, although we did not see a 
difference between the HF and AF groups in large conduit vessel blood flow, we cannot rule out 
differences in postprandial microvascular blood flow responses between groups. 
In summary, we found that HF subjects demonstrated a greater increase in MSNA burst 
incidence following ingestion of a mixed meal in comparison to AF subjects.  Moreover, when 
the MSNA responses were expressed relative to changes in plasma insulin, the HF subjects had a 
greater increase in MSNA for any given change in insulin.  Collectively, these data suggest that, 
in addition to improved peripheral insulin sensitivity, endurance training may also enhance the 
central actions of insulin to increase MSNA following consumption of a mixed meal. 
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Table 2.1 Subject Characteristics 
 
 
 
 
 
 
 
 
 
 
 
VO2peak, peak oxygen uptake. Values are means ± SE. *P<0.05 vs. average fit. 
 
 
 
 
 
 
 
 
 
 
Average Fit High Fit
Age (yr) 26 ± 2 29 ± 2 
Height (cm) 179 ± 2 180 ± 1
Weight (kg) 75 ± 4 74 ± 2
Body Mass Index (kg•m2-1) 23 ± 1 23 ± 1
VO2peak (ml•kg-1•min-1) 43.6 ± 1.3 65.9 ± 1.4 *
VO2peak (L•min-1) 3.3 ± 0.2 4.9 ± 0.2 *
Glucose (mg•dl-1) 92.9 ± 3.7 96.7 ± 2.9
Insulin (uIU•ml-1) 3.6 ± 0.9 2.7 ± 0.3
 
  
Table 2.2  Cardiovascular and hemodynamic responses to a mixed meal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; HR, heart rate. Values are means ± 
SE.   
5
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Table 2.3  Muscle sympathetic nerve activity (MSNA) responses to a mixed meal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AU, arbitrary units.  Values are means ± SE.  *P<0.05 vs. average fit. MSNA total activity and burst strength are only included for 
completeness (see text for details). 
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Figure 2.1  Mean plasma glucose (panel A) and insulin (panel B) at baseline (time 0) and for 
120 minutes following consumption of the mixed meal in the average fit and high fit groups, as 
well as the area under the curve for glucose (panel C) and insulin (panel D).  Values are mean ± 
SE.  *P < 0.05 vs. average fit. 
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Figure 2.2  Original records from an average fit (panel A) and high fit (panel B) subject illustrating muscle sympathetic nerve activity 
(MSNA) and respiratory tracings at baseline and 120 minutes following consumption of the mixed meal.  In response to the mixed 
meal, MSNA burst incidence increased 11 and 23 bursts/100 heart beats in the average fit and high fit subject, respectively. V, volts; 
AU, arbitrary units.
5
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Figure 2.3  Mean muscle sympathetic nerve activity (MSNA) burst incidence responses (panel 
A) at baseline (time 0) and for 120 minutes following consumption of the mixed meal in the 
average fit and high fit groups.  Panel B shows the changes in MSNA burst incidence from 
baseline in both groups. AU, arbitrary units; Hb, heart beats.  Values are mean ± SE.  *P < 0.05 
vs. average fit. 
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Figure 2.4  Group averages for the ratios relating changes from baseline in MSNA burst 
incidence (panel A) to changes in plasma insulin following mixed meal intake.  Panel B shows 
the ratio of MSNA burst incidence area under the curve (AUC0-120) to the insulin AUC0-120.  AU, 
arbitrary units; Hb, heart beats.  Values are mean ± SE.  *P < 0.05 vs. average fit. 
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ABSTRACT 
Recent animal studies indicate that insulin increases arterial baroreflex control of 
lumbar sympathetic nerve activity; however, the extent to which these findings can be 
extrapolated to humans is unknown. To begin to address this, muscle sympathetic nerve 
activity (MSNA) and arterial blood pressure (BP) were measured in 19 healthy subjects 
(27±1 yr) before and for 120 minutes following two common methodologies used to 
evoke sustained increases in plasma insulin, a mixed meal and a hyperinsulinemic 
euglycemic clamp.  Weighted linear regression analysis between MSNA and diastolic 
blood pressure was used to determine the gain (i.e. sensitivity) of arterial baroreflex 
control of MSNA. Plasma insulin was significantly elevated within 30 minutes following 
meal intake (Δ34±6 uIU/ml; P<0.05) and remained above baseline for up to 120 minutes.  
Similarly, after meal intake, arterial baroreflex MSNA gain for burst incidence and total 
MSNA was increased and remained elevated for the duration of the protocol (e.g. burst 
incidence gain: -3.29±0.54 baseline vs. -5.64±0.67 120 minutes bursts/100 heart 
beats/mmHg; P<0.05).  During the hyperinsulinemic euglycemic clamp, in which insulin 
was elevated to postprandial concentrations (Δ42±6 uIU/ml; P<0.05), while glucose was 
maintained constant, arterial baroreflex MSNA gain was similarly enhanced (e.g. burst 
incidence gain: -2.44±0.29 baseline vs. -4.74±0.71 120 minutes bursts/100 heart 
beats/mmHg; P<0.05).  Importantly, during time control experiments, with sustained 
fasting insulin concentrations, the arterial baroreflex-MSNA gain remained unchanged. 
These findings demonstrate, for the first time in healthy humans, that increases in plasma 
insulin enhance the gain of arterial baroreflex control of MSNA. 
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INTRODUCTION 
The arterial baroreflex modulates beat-to-beat oscillations in arterial blood 
pressure via the control of efferent sympathetic outflow to the vasculature.  Due to the 
importance of the arterial baroreflex in the regulation of blood pressure a large body of 
research has been dedicated to understanding alterations in baroreflex sensitivity (i.e. 
gain) in physiological (e.g. exercise) as well as pathophysiological conditions1-3. In 
regards to the latter, numerous studies have indicated that hypertensive conditions are 
typically associated with reductions in arterial baroreflex sensitivity4-7. Interestingly, 
another common risk factor shown to be present in hypertensive patients is insulin 
resistance8, 9.  In this regard, a number of recent studies have indicated that several 
conditions with known reductions in insulin sensitivity also demonstrate impairments in 
arterial baroreflex function and hypertension, including obesity10 and the metabolic 
syndrome11.  Although not causative, the concomitant occurrence of insulin resistance 
with reductions in arterial baroreflex function clearly suggests a link between the two that 
warrants investigation. 
Emerging evidence from studies in experimental animal models has begun to 
establish a role for insulin in the central control of the arterial baroreflex.  Recently, 
Pricher et al12 demonstrated that increases in insulin within the brain, via lateral 
ventricular infusion, enhanced the gain of arterial baroreflex control of lumbar 
sympathetic nerve activity in rats.  Other studies have indicated that neurons in central 
baroreflex regulatory regions (i.e. nucleus tractus solitarius) are responsive to insulin13.  
Collectively, these studies indicate that insulin can directly influence arterial baroreflex 
function within central neural cardiovascular control pathways.  However, to date, no 
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work has been performed in humans evaluating the potential influence of insulin on 
arterial baroreflex control of sympathetic nerve activity, and therefore the extent to which 
these findings in experimental animals can be translated to humans remains unknown. 
Therefore, the purpose of the current study was to examine a role for insulin in 
arterial baroreflex control of sympathetic nerve activity in humans.  Although, insulin is 
not produced in significant amounts within the brain, increases in circulating insulin gain 
access to the central nervous system via transport mediated uptake across the blood brain 
barrier14, 15.  Thus, we utilized two common methodologies to raise plasma insulin 
concentrations.  First, a mixed meal was used as a physiological method to evoke 
increases in plasma insulin.  In addition, to further isolate the influence of insulin on 
arterial baroreflex control we also performed hyperinsulinemic euglycemic clamps, in 
which insulin concentrations were elevated to a similar extent as postprandial conditions, 
without concomitant increases in plasma glucose.  We hypothesized that increases in 
plasma insulin would enhance the gain of arterial baroreflex control of muscle 
sympathetic nerve activity in healthy humans.
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METHODS 
General Procedures 
Nineteen healthy male subjects (age, 27 ± 1 yr; height, 180 ± 1 cm; weight, 80 ± 3 
kg) volunteered for participation in these studies.  No subject had a history or symptoms 
of cardiovascular, pulmonary, metabolic, or neurological disease and none were taking 
medications.  Subjects were instructed to abstain from caffeinated beverages and food for 
12 hours, alcohol for 24 hours, and physical activity for 48 hours prior to the 
experimental sessions.  After receiving a detailed verbal and written explanation of the 
intended experimental protocol and measurements, each subject provided written 
informed consent.  All experimental procedures and protocols conformed to the 
Declaration of Helsinki and were approved by the University of Missouri Health Sciences 
Institutional Review Board.   
 
Experimental Measurements 
Subjects were studied in the supine position at a constant ambient room 
temperature of 22-23 ºC.  Heart rate (HR) was continuously monitored using a lead II 
electrocardiogram.  Arterial blood pressure was measured on a beat-to-beat basis using 
servo-controlled finger photoplethysmography (Finometer, Finapres Medical Systems, 
Amsterdam, Netherlands).  In addition, arterial blood pressure was measured with an 
automated sphygmomanometer (Welch Allyn, Skaneatles Falls, NY, USA) to confirm the 
finometer measurements of absolute blood pressure.  Respiratory movements were 
monitored using a strain-gauge pneumograph placed in a stable position around the 
abdomen (Pneumotrace, UFI, Morro Bay, CA, USA).    
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 Multiunit recordings of postganglionic muscle sympathetic nerve activity 
(MSNA) were obtained by inserting unipolar tungsten microelectrodes percutaneously 
through the intact, unanaesthetized skin and positioned into muscle nerve fascicles of the 
peroneal nerve near the fibular head. The nerve signal was processed by a pre-amplifier 
and an amplifier (Dept. of Bioengineering, University of Iowa, Iowa City, IA), band pass 
filtered (bandwidth 700 – 2000 Hz), rectified, and integrated (time constant, 0.1s) to 
obtain a mean voltage neurogram.  MSNA recordings were identified by their 
characteristic pulse-synchronous burst pattern and increased neural activity in response to 
an end-expiratory apnea or Valsalva maneuver, without any response to arousal stimuli or 
stroking of the skin. MSNA was first identified by visual inspection and was then 
analyzed using custom designed software (MatLab, The Math Works, Natick, MA, 
USA), as previously described16, 17.  The amplitude of the largest burst at baseline was 
assigned a value of 1000 (arbitrary units; AU) and all other bursts within a trial were 
normalized with respect to this value.  All variables were sampled at 1000Hz and stored 
for off-line analysis (Chart v5.2 and Powerlab, ADInstruments, Bella Vista, NSW, 
Australia). 
 Plasma insulin and glucose were measured from venous blood samples drawn 
from an antecubital (Protocol 1) or a hand (Protocol 2 & 3) intravenous catheter.  Insulin 
was determined using chemiluminescent enzyme immunoassay (Immulite 1000 
Analyzer, Diagnostic Products Corp., Los Angeles, CA, USA) and glucose was 
determined using the glucose oxidase method (Thermo, Waltham, MA, USA or Beckman 
Instruments, Brea, CA, USA). 
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Experimental Protocols 
Protocol 1: Arterial Baroreflex Control of MSNA Following a Mixed Meal 
A mixed meal was utilized as a physiological method to evoke sustained increases 
in plasma insulin (n=12).  MSNA, arterial blood pressure, heart rate and respiration were 
measured before and for 120 minutes following ingestion of a liquid mixed meal (Ensure 
Plus, Abbott Laboratories, Columbus, Ohio, USA; 57% CHO, 28% Fat, 15% Protein), 
corresponding to 20% of the subject’s estimated energy expenditure calculated from body 
weight18.  All neuro-cardiovascular variables were measured at baseline for 20 minutes 
and for a 5 minute period, every 30 minutes, following consumption of the mixed meal.  
Venous blood samples were similarly collected from an antecubital intravenous catheter 
and the resulting plasma was stored at -80° C for later analysis of plasma insulin and 
glucose.  
 
Protocol 2: Arterial Baroreflex Control of MSNA During a Hyperinsulinemic 
Euglycemic Clamp 
 To further isolate the influence of insulin on arterial baroreflex control of MSNA, 
hyperinsulinemic euglycemic clamps were performed (n=8) in which insulin was 
elevated to postprandial concentrations while glucose was maintained constant19.  
Intravenous catheters were placed in a left antecubital vein and a right hand vein for the 
infusion of insulin/glucose and blood sampling, respectively.  The right hand was placed 
in a heated box (50° C) for determination of arterialized venous blood samples20.  Insulin 
(Humulin, Eli Lilly, Indianapolis, IN, USA) was diluted in 0.9% saline with 5 ml of the 
subject’s blood and a 10 minute priming insulin infusion was followed by a constant 
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infusion at 30mU/m2/minute, for a total of 120 minutes.  Glucose was maintained at 
euglycemic concentrations throughout via a variable 20% dextrose infusion.  Plasma 
glucose was determined every 5 minutes and plasma insulin was stored at -80° C for later 
analysis.  MSNA, arterial blood pressure, heart rate and respiration were collected for 20 
minutes at baseline and for a 5 minute period, every 30 minutes, during the 
hyperinsulinemic euglycemic clamp. 
 
 
Protocol 3: Arterial Baroreflex Control of MSNA During Time Control Experiments 
In a subset of subjects (n=4) time control experiments were also performed in 
which 0.9% saline was infused to match the volume administered during the 
hyperinsulinemic euglycemic clamp, while insulin was sustained at fasting 
concentrations. 
 
Data Analysis 
Baseline MSNA, arterial blood pressure and heart rate were calculated as mean 
values over a 6 minute period.  Following consumption of the mixed meal and during the 
hyperinsulinemic euglycemic clamp or time controls, 3 minute averages were calculated 
from the 5 min data segments collected every 30 minutes.  The same segments were used 
to evaluate arterial baroreflex control of MSNA by analyzing the relationship between 
spontaneously occurring fluctuations in diastolic blood pressure and MSNA, as 
previously described21-24.  Briefly, the diastolic blood pressure for each cardiac cycle 
within a data collection period was grouped into 3 mmHg pressure bins.  The burst 
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incidence within each pressure bin was calculated by determining the percentage of 
diastoles that were associated with a burst of MSNA and expressed as bursts/100 
heartbeats.  In addition, total MSNA was determined for each pressure bin by calculating 
the total area of all MSNA bursts, relative to the number of cardiac cycles, and expressed 
as arbitrary units (AU)/beat.  The slope of the relationship between MSNA variables and 
diastolic blood pressure was identified using linear regression analysis (SPSS v17.0, 
SPSS Inc, Chicago, IL, USA), with a minimum r value of 0.5 used as a criteria for 
accepting slopes.  The mean r value for all of the time points during each protocol was: 
Protocol 1 - 0.88 ± 0.01 (Range: 0.56-0.99), Protocol 2 - 0.90 ± 0.01 (Range: 0.78-0.99) 
and Protocol 3 - 0.86 ± 0.21 (Range: 0.74-0.98), indicating adequate fit of the linear 
regression analyses.  All data were weighted to account for the number of cardiac cycles 
within each pressure bin; thus removing bias due to bins containing a small number of 
cardiac cycles. The diastolic blood pressure range used for the linear regression analyses 
was approximately 20 mmHg under resting conditions (mixed meal: 21 ± 1, 
hyperinsulinemic euglycemic clamp: 21 ± 2, time control: 19 ± 1) and importantly the 
range was the same at all time points examined.  The slope of the relationship between 
spontaneous fluctuations in MSNA burst incidence and diastolic blood pressure was 
recently shown to be highly correlated with slopes derived using the more invasive 
modified Oxford approach for assessing arterial baroreflex-MSNA gain (i.e. bolus 
sodium nitroprusside and phenylephrine)25.  In addition, van Schelven et al26 have 
demonstrated that arterial baroreflex burst incidence gain was not altered from baseline 
during steady state nitroprusside infusions in which MSNA was robustly increased.  
Collectively, these data highlight the usefulness of the burst incidence-diastolic blood 
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pressure measures in assessing arterial baroreflex function; particularly in conditions in 
which multiple repeated measures are needed, such as in the current study following 
mixed meal intake and during a 2 hour hyperinsulinemic euglycemic clamp.   
 
Statistical Analysis  
 Univariate repeated measures ANOVA was used and significant main effects 
were evaluated with Bonferroni post-hoc analyses when appropriate.  Statistical 
significance was set at P < 0.05.  Results are presented as mean ± standard error (SE). 
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RESULTS 
Increased arterial baroreflex MSNA gain following a mixed meal 
 Mixed meal intake induced a significant rise in plasma insulin, as well as plasma 
glucose (Figure 3.1).  The arterial baroreflex gain of MSNA burst incidence (Figure 
3.2A) was significantly enhanced (i.e. more negative) within 30 minutes (Δ-1.91±0.53 
bursts/100 heart beats/mmHg) and remained elevated for the duration of the study (e.g. 
120 minutes: Δ-1.82±0.37 bursts/100 heart beats/mmHg).  Similarly, arterial baroreflex 
control of total MSNA (Figure 3.2B) was increased at 30 minutes, and thereafter 
remained above baseline up to 120 minutes. 
 
Increased arterial baroreflex MSNA gain during a hyperinsulinemic euglycemic 
clamp 
During the hyperinsulinemic euglycemic clamp, plasma insulin was increased 
similarly to after the mixed meal; however, euglycemia was maintained throughout at 
fasting concentrations (Figure 3.1).  Importantly, in line with the findings from the mixed 
meal, robust increases in the gain of arterial baroreflex control of MSNA burst incidence 
(e.g. 120 minutes: Δ-2.30±0.62 bursts/100 heart beats/mmHg) and total MSNA were 
observed with the concomitant increase in plasma insulin.  In contrast, during the time 
control experiments, in which plasma insulin and glucose were not changed (data not 
shown), the gain of the arterial baroreflex was not different from baseline at any time 
point (Figure 3.3).   
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MSNA and cardiovascular parameters  
As anticipated, following the mixed meal and during the hyperinsulinemic 
euglycemic clamp, MSNA burst frequency, burst incidence and total MSNA were 
increased within 30 minutes and remained above baseline for the remainder of the 
protocol.  Systolic and diastolic blood pressures, as well as heart rate, were slightly, but 
significantly increased following consumption of the mixed meal.  Arterial blood 
pressure and heart rate remained unchanged during the hyperinsulinemic euglycemic 
clamp and time control experiments (Table 3.1).   
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DISCUSSION 
The primary novel finding of this investigation is that increases in plasma insulin 
enhanced the gain of arterial baroreflex control of MSNA.  Indeed, physiological 
elevations in plasma insulin following the mixed meal were associated with an increased 
slope of the relationship between diastolic blood pressure and MSNA.  Furthermore, 
during the hyperinsulinemic euglycemic clamp, in which insulin was increased to 
postprandial concentrations, while glucose was maintained at euglycemia, arterial 
baroreflex control of MSNA burst incidence was also augmented.  Overall, these findings 
strongly support a role for insulin in the modulation of the sympathetic arterial baroreflex 
in healthy humans. 
In addition to the well described sympathoexcitatory effect(s) of insulin27, 28, 
recent findings obtained in animals illustrate a role for insulin in the central modulation 
of the arterial baroreflex12.  During lateral ventricular infusion of insulin in rats, robust 
increases in the gain of arterial baroreflex control of lumbar sympathetic nerve activity 
have been demonstrated; illustrating that acute increases in insulin within the brain 
modulate arterial baroreflex control of sympathetic outflow12.  The findings from the 
current study support and extend these findings by demonstrating for the first time in 
healthy humans that acute increases in insulin are associated with an enhanced arterial 
baroreflex MSNA gain.  Importantly, the enhanced sympathetic arterial baroreflex 
control was noted during modest increases in plasma insulin under both postprandial 
(mixed meal) and experimental (insulin clamp) conditions; supporting a role for insulin 
within a normal physiological range in the modulation of the arterial baroreflex. 
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Insulin is not produced in large quantities in the central nervous system; however 
plasma insulin gains access to the brain via saturable transport-mediated uptake across 
the blood brain barrier14, 15.  As such, circulating insulin can influence arterial baroreflex 
control via central neural pathways and indeed, insulin receptors are present in numerous, 
yet distinct cardiovascular regulatory regions, including hypothalamic and brainstem 
regions29, 30.  In this context, Schwartz et al31 have previously demonstrated in dogs that 
cerebrospinal fluid concentrations of insulin are increased within 30 minutes after 
systemic infusion of insulin; in line with our finding of an increase in arterial baroreflex 
MSNA gain within 30 minutes after the mixed meal or during the hyperinsulinemic 
euglycemic clamp.  Moreover, the half life of insulin within cerebrospinal fluid has been 
reported to be approximately 140 minutes32, which may explain the sustained 
enhancement in arterial baroreflex control of MSNA demonstrated in the current study. 
Interestingly, the increase in arterial baroreflex MSNA gain was noted for the 
relationships between diastolic blood pressure and both, MSNA burst incidence as well 
as total MSNA.  In this regard, previous investigations have suggested that the 
occurrence of a sympathetic burst (incidence) and the area of a burst may reflect distinct 
central sites involved in arterial baroreflex control of MSNA21, 22.  The current data 
demonstrate that during elevations in insulin, for a given change in diastolic blood 
pressure there is a greater change in MSNA burst incidence and total MSNA (area/beat), 
relative to fasting conditions.  As such, our findings suggest that insulin may influence 
central pathways involved in both the occurrence of a burst of MSNA as well as the size 
of a given burst.  Due to the peripheral vasodilatory effect of insulin, the physiological 
significance of an enhanced arterial baroreflex control over the occurrence and size of a 
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burst of MSNA may provide optimal protection of arterial blood pressure during acute 
elevations in plasma insulin.  Interestingly, it should be noted that arterial blood pressure 
was well maintained throughout the mixed meal and hyperinsulinemic euglycemic clamp 
in the present study.  Furthermore, autonomic failure patients demonstrate robust falls in 
arterial blood pressure after meal consumption33, illustrating the importance of the 
sympathetic nervous system in the maintenance of blood pressure during periods of 
increased circulating insulin. 
Of note, although we found an increase in arterial baroreflex gain for the control 
of MSNA burst occurrence and area (i.e. total MSNA), methodological considerations of 
the use of MSNA burst incidence, in comparison to total MSNA, to derive spontaneous 
baroreflex measures is warranted.  In this regard, previous findings have demonstrated 
that the gain of arterial baroreflex control of MSNA burst incidence was similar to 
baroreflex sensitivities obtained using pharmacological manipulations of arterial blood 
pressure25, 26; demonstrating the usefulness of these measurements.  In contrast, 
spontaneous arterial baroreflex gains calculated from measurements using MSNA burst 
area (e.g. total MSNA) have been suggested to be influenced more by non baroreflex 
inputs22, 25, which may limit the interpretation of such measures.  Indeed, several studies 
have reported weak relationships between burst area and diastolic blood pressure, 
whereas burst incidence consistently demonstrates strong relationships with diastolic 
blood pressure21-23, 25, 34.  Thus, although robust increases in arterial baroreflex control of 
total MSNA were observed following the mixed meal and during the hyperinsulinemic 
euglycemic clamp, we focused our interpretation on baroreflex measures of burst 
incidence. 
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 From these human studies, although we cannot determine the precise region(s) of 
insulin action on arterial baroreflex control of MSNA, several areas are worthy of 
consideration.  The aforementioned work in rats using lateral ventricular infusion of 
insulin suggests a hypothalamic region, such as the paraventricular nucleus, may play a 
major role12.  In addition, neurons from brainstem regions involved in arterial baroreflex 
afferent processing (e.g. nucleus tractus solitarius) are responsive to insulin13.  
Furthermore, neural projections from the circumventricular organs, which lack a blood 
brain barrier, could also impact arterial baroreflex function during elevations in plasma 
insulin15.  Indeed, the investigation of insulin effects on arterial baroreflex control of 
sympathetic outflow is in its infancy; however this area undoubtedly deserves further 
attention. 
 
Perspectives 
 A number of conditions are characterized by reductions in arterial baroreflex gain, 
including hypertension4-7, obesity10, metabolic syndrome11 and pregnancy35, 36.  In 
addition, emerging evidence indicates that insulin resistant states are accompanied by 
reduced cerebrospinal fluid insulin concentrations, likely emanating from an attenuated 
transport of insulin into the central nervous system35-40.  In line with this, Brooks and 
colleagues have advanced the hypothesis that a certain level of insulin within the brain is 
essential for normal arterial baroreflex function12.  The present study lends support to this 
growing body of literature by demonstrating for the first time that insulin can modulate 
the sympathetic arterial baroreflex in healthy humans.  However, whether chronic 
alterations in insulin transport and/or signaling in the central nervous system contribute to 
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a decreased sympathetic arterial baroreflex gain in insulin resistant conditions remains to 
be determined.  Given the importance of the arterial baroreflex in the regulation of 
arterial blood pressure, clearly future studies, from experimental animals to humans, are 
warranted to delineate the precise neural pathways and mechanism(s) of insulin action on 
neurocardiovascular control in health and disease.  
 In summary, for the first time, we found that physiological increases in plasma 
insulin following a mixed meal and during a hyperinsulinemic euglycemic clamp 
enhanced the gain of arterial baroreflex control of MSNA in humans.  Collectively, these 
findings extend recent studies in animals and strongly support a role for insulin in the 
modulation of the sympathetic arterial baroreflex. 
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Table 3.1  Sympathetic nerve activity and cardiovascular responses to a mixed meal, hyperinsulinemic euglycemic clamp and time 
control experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSNA, muscle sympathetic nerve activity; Hb, heart beats; AU, arbitrary units.  Values are means ± SE.  *P<0.05 vs. baseline.
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Figure 3.1  Mean plasma insulin (panel A) and glucose concentrations (panel B) at 
baseline (time 0) and for 120 minutes following consumption of the mixed meal and 
during the hyperinsulinemic euglycemic clamp. 
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Figure 3.2  Summary data illustrating the gain of arterial baroreflex control of muscle 
sympathetic nerve activity (MSNA) burst incidence (panel A) and total MSNA (panel B) 
at baseline (time 0) and for 120 minutes following consumption of the mixed meal.  Hb, 
heart beats; AU, arbitrary units.  *P<0.05 vs. baseline. †P<0.05 vs. 30 minutes. 
Time (min)
0 30 60 90 120
To
ta
l M
SN
A 
G
ai
n 
(A
U
/b
ea
t/m
m
H
g)
-12
-10
-8
-6
-4
-2
0
*
*
*
*
†
B)
Time (min)
0 30 60 90 120
M
SN
A 
Bu
rs
t I
nc
id
en
ce
 G
ai
n 
(b
ur
st
s/
10
0 
H
b/
m
m
H
g)
-6
-4
-2
0
*
*
*
*
A)
To
ta
l M
SN
A 
G
ai
n 
(A
U
/b
ea
t/m
m
H
g)
To
ta
l M
SN
A 
G
ai
n 
(A
U
/b
ea
t/m
m
H
g)
M
SN
A 
Bu
rs
t I
nc
id
en
ce
 G
ai
n 
(b
ur
st
s/
10
0 
H
b/
m
m
H
g)
M
SN
A 
Bu
rs
t I
nc
id
en
ce
 G
ai
n 
(b
ur
st
s/
10
0 
H
b/
m
m
H
g)
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3  Summary data illustrating the gain of arterial baroreflex control of muscle 
sympathetic nerve activity (MSNA) burst incidence (panel A) and total MSNA (panel B) 
at baseline (time 0) and for 120 minutes during the hyperinsulinemic euglycemic clamp 
and time control experiments.  Hb, heart beats; AU, arbitrary units.  *P<0.05 vs. baseline.  
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ABSTRACT 
Type II diabetes is associated with acute and chronic alterations in the regulation 
of arterial blood pressure.  However, whether impairments in arterial baroreflex control 
of sympathetic nerve activity contribute to alterations in blood pressure control in 
diabetic patients remains unclear. To begin to address this question, muscle sympathetic 
nerve activity (MSNA), and arterial blood pressure were continuously recorded in 8 type 
II diabetic patients and 6 healthy age, sex and body weight-matched control subjects 
during intravenous bolus injections of sodium nitroprusside followed 60s later by 
phenylephrine hydrochloride. The gain (i.e. sensitivity) of arterial baroreflex-MSNA 
control was identified from the linear relationships between total MSNA and diastolic 
blood pressure.  The overall arterial-MSNA gain, which encompasses the MSNA 
responses to both a fall and rise in arterial blood pressure, was similar between the two 
groups (-6.96±1.17 diabetics vs. -6.54±1.17 controls, AU/beat/mmHg; P=0.45).  
Similarly, when the responses were examined separately for falls (-8.87±1.37 diabetics 
vs. -8.58±1.74 controls, AU/beat/mmHg; P=0.22) and rises (-6.57±1.24 diabetics vs. -
6.49±1.13 controls, AU/beat/mmHg; P=0.44) in arterial blood pressure, no differences in 
arterial baroreflex control of MSNA were noted.  These preliminary data suggest that 
patients with type II diabetes exhibit preserved arterial baroreflex control of sympathetic 
nerve activity.
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INTRODUCTION 
Arterial baroreceptors originating in the carotid artery and the aorta play a pivotal 
role in the rapid reflex adjustments that accompany acute cardiovascular stressors1, 2.  
Indeed, the ability to withstand acute falls and rises in blood pressure is dependent on a 
properly functioning arterial baroreflex2.  In particular, arterial baroreflex control of 
sympathetic nerve activity to the peripheral vasculature is crucial for normal control of 
blood pressure3-5.  Although previous findings have indicated that patients with type II 
diabetes mellitus exhibit postural hypotension6-8, greater blood pressure reactivity to 
acute cardiovascular stressors9-11, and an increased risk for the development of 
hypertension12, the extent to which impairments in arterial baroreflex regulation 
contribute to these alterations in blood pressure control remains unclear. 
Recent findings from experimental animal models of type II diabetes have 
provided insight into arterial baroreflex regulation of sympathetic nerve activity.  In this 
regard, studies in the obese Zucker rat have demonstrated an impaired arterial baroreflex 
control of splanchnic sympathetic nerve activity13, 14.  While adult obese Zucker rats do 
exhibit characteristics of type II diabetes, such as hyperinsulinemia and hyperglycemia, 
they are often hypertensive15.  Therefore, the extent to which these findings in 
experimental animals can be translated to normotensive type II diabetic patients remains 
unknown.  Investigations reporting a diminished increase in plasma norepinephrine, in 
response to standing, in diabetic patients suggests an impairment in the sympathetic arc 
of the baroreflex16.  However, to date, no studies have directly examined arterial 
baroreflex control of sympathetic nerve activity in type II diabetes patients.   
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 A further consideration when examining the arterial baroreflex, is the inherent 
asymmetry in the baroreflex-mediated responses to falls and rises in arterial blood 
pressure (i.e. hysteresis).  In this context, differences in sympathetic baroreflex gain 
during increases versus decreases in blood pressure have been recently described in 
healthy adults17.  As such, it appears necessary to account for the direction of pressure 
change when examining the sympathetic baroreflex in type II diabetic patients.  Indeed, 
group differences in arterial baroreflex-mediated responses could potentially be masked 
by combining pressure falls and rises17, 18. 
 With this background in mind, the aim of the current study was to characterize 
sympathetic and cardiovagal arterial baroreflex control in patients with type II diabetes.  
Pharmacological induced decreases and increases in arterial blood pressure were used as 
a robust stimulus while the resultant changes in muscle sympathetic nerve activity 
(MSNA) and cardiac interval were assessed.  Furthermore, given that type II diabetic 
patients exhibit alterations in blood pressure control during both falls and rises in blood 
pressure, a secondary aim was to investigate baroreflex-mediated responses during 
directional changes in blood pressure separately.  We hypothesized that type II diabetic 
patients would exhibit a decreased sympathetic and cardiovagal arterial baroreflex gain to 
both increases and decreases in arterial blood pressure, when compared to healthy age, 
sex and body weight matched control subjects. 
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METHODS 
To date, 8 type II diabetic patients and 6 healthy age, sex and body weight 
matched control subjects have been studied.  Diabetic subjects were all normotensive and 
were not being treated for hypertension, were free of signs of neuropathy, and had no 
history of cardiovascular disease.  Patients were on a stable drug regimen for at least 3 
months prior to participating in the study which included biguanides (n=7), sulfonylureas 
(n=5), insulin (n=4), incretin mimetic (n=1), statins (n=7), angiotensin converting 
enzyme inhibitor (n=1) and hydrochlorothiazide (n=2).  All medications were withheld 
for a minimum of 12 hours prior to the experimental visit.  All experimental procedures 
and protocols were approved by the University of Missouri Health Sciences Institutional 
Review Board and each subject provided written informed consent prior to participation. 
 
Experimental Measurements 
Studies were performed at an ambient room temperature of 22-24 ºC with external 
stimuli minimized.  Heart rate was continuously monitored using a lead II 
electrocardiogram (Quinton Q710, Bothell, WA, USA).  Beat-to-beat arterial blood 
pressure was obtained using servo-controlled finger photoplethysmography (Finometer, 
Finapres Medical Systems, Amsterdam, Netherlands).  In addition, an automated 
sphygmomanometer (Welch Allyn, Skaneatles Falls, NY, USA) was used to measure 
arterial blood pressure by auscultation of the brachial artery and to confirm Finometer 
measurements.  Respiratory movements were monitored using a strain-gauge 
pneumograph placed in a stable position around the abdomen (Pneumotrace, UFI, Morro 
Bay, CA, USA).  Multiunit recordings of postganglionic MSNA were obtained as 
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described previously19-21.  Briefly, a unipolar tungsten microelectrode was inserted 
percutaneously through the intact, unanaesthetized skin and positioned into muscle nerve 
fascicles of the peroneal nerve near the fibular head of the left leg. Postganglionic 
sympathetic action potentials were amplified, filtered (bandwidth 700 – 2000 Hz), 
rectified, and integrated (time constant, 0.1 s) to obtain a mean voltage neurogram (Dept. 
of Bioengineering, University of Iowa, Iowa City, IA).  MSNA recordings were 
identified by their characteristic pulse-synchronous burst pattern and increased neural 
activity in response to an end-expiratory apnea or Valsalva maneuver, without any 
response to arousal stimuli or stroking of the skin22-24.  Heart rate, arterial blood pressure, 
respiration and MSNA were sampled at 1000Hz and stored for off-line analysis (Chart 
v5.2 and Powerlab, ADInstruments, Bella Vista, NSW, Australia). 
 
Experimental Protocol 
 Subjects were instructed to refrain from food and caffeinated beverages for 12 
hours and strenuous physical activity and alcohol for 24 hours prior to reporting to the 
laboratory.  Subjects were placed in the supine position on a medical examination table 
and an intravenous catheter was placed in an antecubital vein.  Fasting blood samples 
were drawn for the measurement of triglycerides, cholesterol, lipoproteins, glucose and 
insulin.  Following instrumentation for measures of heart rate, arterial blood pressure, 
respiration and MSNA, baseline variables were collected for a period of 20 minutes.  
Subsequently, sympathetic arterial baroreflex control was investigated using the modified 
Oxford technique25. MSNA, heart rate and blood pressure were continuously recorded 
while rapid pharmacologically-induced changes in blood pressure were elicited using 
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intravenous injections of sodium nitroprusside (100 µg) to lower blood pressure 
approximately 15 mmHg, followed 60 seconds later by phenylephrine hydrochloride 
(150-175 µg) to raise blood pressure above baseline levels.  Two to three trials were 
performed for each subject with a minimum of 15 minutes between trials to allow for re-
establishment of baseline cardiovascular and sympathetic variables. 
 
Data Analysis 
MSNA was first identified by visual inspection and was then analyzed using 
custom designed software (MatLab, The Math Works, Natick, MA, USA), as previously 
described21, 26.  The amplitude of the largest burst at baseline was assigned a value of 
1000 (arbitrary units; AU) and all other bursts within a trial were normalized with respect 
to this value.  A 10 minute segment was used for the calculation of baseline variables.   
 
Sympathetic Arterial Baroreflex Gain 
 Arterial baroreflex control of MSNA was determined by examining the 
relationship between MSNA and diastolic blood pressure (DBP) during the bolus drug 
infusions.  DBP was chosen, as it has been shown to relate most closely with MSNA.  
Each modified Oxford trial was analyzed in 3 segments17, 27: First, overall arterial 
baroreflex gain was determined from the point at which blood pressure decreased 
following infusion of sodium nitroprusside until the blood pressure peak following 
phenylephrine hydrochloride infusion; thus encompassing the MSNA response to both a 
decrease and an increase in arterial blood pressure.  The sympathetic responses to acute 
hypotension and hypertension were also separately examined using the segments from 
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the onset of the blood pressure drop after nitroprusside infusion until the nadir of the 
blood pressure change, and from the lowest blood pressure after phenylephrine 
administration until the blood pressure peak, respectively.  The DBP within each segment 
was grouped into 3 mmHg pressure bins and total MSNA was determined within each 
pressure bin by calculating the total area of all MSNA bursts, relative to the number of 
cardiac cycles, and expressed as arbitrary units (AU) / beat.  All data 3 mmHg above the 
greatest pressure associated with a burst of MSNA were excluded from analysis in order 
to ensure that the derived baroreflex sensitivity reflected primarily the linear portion of 
the arterial baroreflex curve.  The slope of the relationship between MSNA and DBP was 
identified using linear regression analysis (SPSS v17.0, SPSS Inc, Chicago, IL, USA) and 
used as a calculation of sympathetic arterial baroreflex gain.  A minimum r value of 0.5 
was used as a criterion for accepting slopes.  All data were weighted to account for the 
number of cardiac cycles within each pressure bin; thus removing bias due to bins 
containing a small number of cardiac cycles.  Each modified Oxford trial was analyzed 
separately for each individual and then the gains from each trial were averaged together 
to provide a mean for each subject.   
 
Statistical Analysis 
 Group comparisons for baseline variables, as well as sympathetic arterial 
baroreflex gains derived from the bolus drug infusions for the overall, falls and rises in 
blood pressure were compared using unpaired Student t-tests.  Statistical significance was 
set at P<0.05 and results are presented as means ± standard error (SE). 
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RESULTS 
 The type II diabetic patients were similar to the control subjects for age, height, 
weight and body mass index.  As anticipated, plasma glucose and hemoglobin A1c were 
higher in the diabetic patients.  In addition, fasting insulin tended to be higher in the 
patient group (P=0.12) whereas cholesterol, lipoproteins and triglycerides were not 
different between the type II diabetic patients and healthy controls (Table 4.1).   
Baseline heart rate, systolic, diastolic and mean arterial blood pressures were the 
same between groups.  In addition, MSNA burst frequency and burst incidence indicated 
similar resting sympathetic nerve activity between the type II diabetic patients and 
healthy age, sex and body weight matched control subjects (Table 4.2). 
 
Sympathetic Baroreflex Gain 
 Original relationships illustrating the derived arterial baroreflex-MSNA gains for 
one diabetic subject and a matched control subject are presented in Figure 4.1.  The 
overall baroreflex gain during the bolus drug infusions, which encompasses the MSNA 
responses to both a fall and rise in arterial blood pressure, indicated similar sympathetic 
arterial baroreflex sensitivity in the type II diabetic subjects when compared to the 
control group.  Furthermore, the sympathetic baroreflex gains during the acute decreases 
and increases in blood pressure were similar between groups (Figure 4.2). 
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DISCUSSION 
 The purpose of the present study was to examine arterial baroreflex control of 
sympathetic nerve activity in patients with type II diabetes.  Contrary to our hypothesis, a 
comparable overall sympathetic arterial baroreflex gain was found between diabetic 
patients and healthy control subjects.  These similarities in arterial baroreflex-MSNA 
gain were also evident when the responses were examined to falls and rises in arterial 
blood pressure separately.  These preliminary findings indicate that arterial baroreflex 
control of MSNA is well preserved in type II diabetic subjects. 
 Type II diabetes is associated with acute and chronic alterations in the regulation 
of arterial blood pressure6-12, although the underlying mechanisms remain incompletely 
defined.  Indeed, during acute postural challenges, robust falls in blood pressure have 
been documented in diabetic patients6-12.  In addition, type II diabetic patients exhibit an 
exaggerated blood pressure response to physiological stressors, such as exercise9-11, and 
are highly prone to develop hypertension12.  Given that the arterial baroreflex is crucial 
for beat-to-beat and potentially long term regulation of arterial blood pressure, we 
reasoned that arterial baroreflex control of MSNA would be impaired in the presence of 
type II diabetes.  Interestingly, we found, that when the system was stressed across a wide 
range of pressures, overall arterial baroreflex-MSNA gain appeared normal in otherwise 
healthy, normotensive type II diabetic patients. 
 To date, limited information exists on arterial baroreflex control of sympathetic 
outflow in type II diabetic conditions.  Findings in the obese Zucker rat, a commonly 
used model of type II diabetes, have indicated an impaired arterial baroreflex control of 
splanchnic sympathetic nerve activity13, 14.  In these previous studies, the greatest 
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decrement in arterial baroreflex function was noted in adult rats, when overt diabetes, 
obesity and hypertension are present.  Although, impairments in arterial baroreflex 
control were also noted in juvenile obese Zucker rats before the development of 
hypertension, comparisons of these animals were made to lean controls.  Therefore, 
whether the reported decrease in arterial baroreflex control of sympathetic nerve activity 
was due to obesity or metabolic disturbances is unclear.  To the best of our knowledge, 
this is the first study in type II diabetic humans utilizing direct recordings of efferent 
sympathetic outflow to examine the sympathetic arterial baroreflex.  Our two subject 
groups were well matched, except for the occurrence of type II diabetes; strengthening 
the conclusion that type II diabetes alone does not alter arterial baroreflex control of 
MSNA.  However, care should be taken when extending these findings to patients with a 
longer duration of diabetes, or conditions in which type II diabetes and other 
comorbidities (i.e. hypertension) concomitantly exist. 
 Although it was originally proposed that asymmetry did not exist in the 
sympathetic arm of the baroreflex28, a recent reexamination by Taylor and colleagues17 
has demonstrated hysteresis in arterial baroreflex-MSNA gain during the modified oxford 
technique.  Therefore, in the present study, we considered the baroreflex-mediated 
sympathetic responses to nitroprusside and phenylephrine separately.  In support of the 
findings for overall gain, we found no difference in arterial baroreflex control of MSNA 
during acute falls and rises in pressure between the type II diabetic patients and healthy 
controls.  This is an important consideration, given that differences in arterial baroreflex 
function could potentially be masked if the direction of pressure change is not taken into 
account17, 18.  Indeed, Studinger et al17 reported that age-related differences in arterial 
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baroreflex-MSNA gain were only revealed when the data were examined in response to 
hypo- and hypertension separately.  
 The measurement of the sympathetic baroreflex in the present study considers the 
entire arterial baroreflex arc; from the input into the system (arterial blood pressure) to 
the ensuing sympathetic response (MSNA).  Thus, the derived gains comprehensively 
reflect arterial baroreflex afferent input, to central processing, to the resultant efferent 
output.  Each of these points in the baroreflex arc work in concert to determine the 
integrated baroreflex response.  In this regard, although we did not see differences 
between type II diabetic patients and controls in the “whole loop” baroreflex gains, it is 
still plausible that a diabetic state may alter a specific portion of the reflex.  A reduction 
in baroreflex afferent signaling could be compensated for by an enhancement in the 
central neural processing, and vice versa, thus resulting in a preserved arterial baroreflex 
gain.  Although speculative, in support of this idea, complex interactions between the 
afferent and efferent arcs for the cardiac baroreflex have recently been described during 
pharmacologically induced changes in blood pressure in healthy subjects27. 
 Several previous findings have suggested that type II diabetes is associated with 
overactive sympathetic outflow to skeletal muscle29, 30.  Interestingly, we found no 
difference in resting MSNA, expressed as burst frequency or burst incidence, between the 
diabetic patients and healthy controls.  Although the reason for the discrepancy between 
the current findings and earlier work is unknown, it should be noted that in previous 
studies the type II diabetic patients were slightly older and had a higher resting arterial 
blood pressure (mean arterial pressure ~100mmHg) than the patient population in the 
present study.  However, in line with our findings, plasma norepinephrine levels have 
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been reported to be similar or lower in type II diabetic patients, when compared to 
healthy control subjects31, 32.  
 In summary, the results from the present study demonstrate that the overall gain 
for arterial baroreflex control of MSNA was similar between type II diabetic patients and 
healthy age, sex and body weight matched control subjects.  The similarities in arterial 
baroreflex gain were also evident when examining the responses to acute hypo- and 
hypertension separately.  These preliminary findings indicate a preserved arterial 
baroreflex control of MSNA in patients with type II diabetes. 
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Table 4.1  Subject Characteristics 
 
Values are means ± SE. *P<0.05 vs. controls. 
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Table 4.2  Resting Cardiovascular and Muscle Sympathetic Nerve Activity (MSNA) 
Hb, heart beats.  Values are means ± SE.  
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Figure 4.1  Examples of the derivation of arterial baroreflex control of muscle 
sympathetic nerve activity (MSNA) in one healthy control subject and one type II 
diabetic patient for overall baroreflex gain (Panel A), as well as the response to a fall 
(Panel B) and rise (Panel C) in arterial blood pressure. AU, arbitrary units; R2, coefficient 
of determination. 
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Figure 4.2  Group summary data for overall baroreflex gain (Panel A), as well as the 
response to a fall (Panel B) and rise (Panel C) in arterial blood pressure. AU, arbitrary 
units.  Values are means ± SE. 
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Chapter 5.  Discussion 
 
Summary of Results 
 Although well recognized for metabolic regulation, a growing body of evidence 
has clearly established a role for insulin in the central control of cardiovascular control.  
Direct administration of insulin into the brain of experimental animals1-3, or acute 
elevations in plasma insulin in healthy humans4-12, result in robust increases in peripheral 
sympathetic nerve activity.  In addition to evoking increases in sympathetic outflow, 
recent work in rats has reported a modulatory role for insulin in the regulation of arterial 
baroreflex control of sympathetic nerve activity2.  The projects presented within this 
report support and extend this emerging area of research by:  1) Demonstrating an 
influence of insulin sensitivity on insulin-mediated sympathoexcitation. 2) Illustrating a 
role for insulin in the modulation of arterial baroreflex control of sympathetic nerve 
activity in healthy humans. 3) Translation of this area of research to an insulin resistant 
disease setting of type II diabetes mellitus. 
 In Aim 1, we sought to examine if an insulin sensitive state, such as chronic 
endurance training, enhances insulin-stimulated increases in central sympathetic outflow.  
Following consumption of a mixed meal, as a physiological stimulus to increases plasma 
insulin, we found that high fit subjects demonstrated a greater increase in muscle 
sympathetic nerve activity (MSNA) burst incidence compared to average fit subjects.  
Interestingly, when MSNA responses were expressed relative to plasma insulin, high fit 
subjects exhibited a greater change in MSNA for any given change in insulin.  
Collectively, these data suggest that, in addition to improved peripheral insulin 
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sensitivity, an insulin sensitive state (i.e. endurance training) may also enhance the 
central actions of insulin to increase MSNA. 
 In the second set of experiments we demonstrate, for the first time, a role for 
insulin in the modulation of the arterial baroreflex in humans.  During increases in 
plasma insulin, under both physiological (mixed meal) and experimental (insulin clamp) 
conditions, an enhanced gain of arterial baroreflex control of MSNA was noted.  These 
findings are in line with recent literature obtained in rats2 and strongly support a role for 
insulin in the control of the sympathetic arterial baroreflex in healthy humans. 
 Given that cerebral spinal fluid levels of insulin are reduced in insulin resistant 
conditions13-17 and that insulin enhances arterial baroreflex control of sympathetic 
outflow (Aim 2), we began to translate our research to a clinically relevant setting of 
insulin resistance in Aim 3.  The gain of the sympathetic arterial baroreflex was 
investigated during pharmacologically induced changes in arterial blood pressure in type 
II diabetic patients and healthy age, sex and body weight matched control subjects.  
Interestingly, we found comparable overall sympathetic arterial baroreflex gains between 
the diabetic patients and healthy control subjects.  These similarities in arterial 
baroreflex-MSNA gain were also evident when the responses were examined to falls and 
rises in arterial blood pressure separately.  Overall, these findings suggest that arterial 
baroreflex control of sympathetic outflow is preserved in otherwise healthy, 
normotensive type II diabetic patients.   
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Future Directions 
 The investigation of insulin effects on neural-cardiovascular control is in its 
infancy and although the results from the present investigations support a role for insulin 
in the control of central sympathetic outflow in humans, this area of research undoubtedly 
deserves further attention.  Potential implications of the findings from each Aim, as well 
as areas for future research are presented below. 
The findings in Aim 1 clearly demonstrate that insulin sensitivity influences 
insulin-stimulated increases in central sympathetic outflow.  These findings are in line 
with previous investigations which have suggested that the central stimulatory actions of 
insulin may be blunted in insulin resistant conditions18-21.  To date, the exact 
mechanism(s) contributing to alterations in insulin stimulated changes in central 
sympathetic outflow to skeletal muscle remain unknown.  Work illustrating that diet and 
pharmacologically induced insulin resistance results in decreased uptake of insulin into 
the brain, suggests that insulin delivery and/or rate of transport into the brain may be 
involved13, 14.  However, the exact molecular mechanisms involved in the control of 
insulin transport into the central nervous system remain incompletely characterized.  
Indeed, the transporter and or receptor responsible remains unknown, although the insulin 
receptor itself has been suggested17, 22, 23.  In addition, it is possible that central insulin-
mediated signaling cascade pathways may be altered with changes in central insulin 
sensitivity.  Findings from rodent models suggest that insulin stimulated increases in 
sympathetic outflow to skeletal muscle primarily occur through the PI3K pathway3.  
Given that this pathway have been shown to be modified in the periphery in insulin 
resistant states24 and in response to endurance training25, it is plausible that alterations in 
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insulin signaling pathways within the central nervous system occur with changes in 
insulin sensitivity.  In line with this, the precise neural pathways and signaling 
mechanisms involved in insulin mediated increases in central sympathetic outflow 
deserve further attention.  Interestingly, work in neuronal cell lines suggests that 
downstream molecules in the insulin signaling cascade, such as protein kinase C, 
modulate glutamatergic N-methyl-D-aspartic acid trafficking and gating26.  Furthermore, 
a potential role for PI3K in the modulation of gamma amino butyric acid, the inhibitory 
neurotransmitter within the central nervous system, function has also been suggested27.  
These findings lend insight into insulin as a complex neuromodulator of excitatory and 
inhibitory neurotransmission; although future studies are clearly warranted. 
 Recent findings in rats have demonstrated a role for insulin in the modulation of 
arterial baroreflex control of sympathetic nerve activity2 and in Aim 2 we extended these 
findings by providing evidence for the first time that insulin increases arterial baroreflex-
MSNA gain in healthy humans.  However, due to the inherent limitations of human 
investigation, we cannot determine the precise site of insulin action on arterial baroreflex 
control.  The aforementioned work in rats clearly suggests that central brain regions are 
involved; although as mentioned above the precise cellular and molecular mechanism(s) 
of insulin action on central neural pathways remains to be elucidated.  In addition, the 
potential for insulin to modulate afferent baroreflex input cannot be discounted, although 
no data exists to date investigating this particular pathway.   
 In addition to examining a role for acute increases in insulin to modulate the 
arterial baroreflex, we began to translate this area of research to a condition of chronic 
insulin resistance.  Interestingly we found that arterial baroreflex control of sympathetic 
115 
 
nerve activity was preserved in patients with type II diabetes when compared to healthy 
control subjects.  Although preliminary, the lack of a group difference in Aim 3, raises 
important questions about acute versus chronic influences of insulin on arterial baroreflex 
function.  Furthermore, investigation of disease populations is complex and consideration 
for numerous other disease-related factors that may work in concert with and/or against 
insulin should be considered.  Given the increasing incidence of type II diabetes, as well 
as numerous other insulin resistant conditions, future mechanistic studies from 
experimental animals to humans examining the interaction of the metabolic and neural-
cardiovascular systems undoubtedly deserves further attention. 
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